Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways
Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways
Patient Name: Member Number: Pathology: Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op
__1st Line __2nd Line __3rd Line __3rd Line+ __Maintenance Biomarkers/Characteristics: (Select all that apply) ALK: __Positive __Negative __Not reported EGFR: __Mutation __Wild type __Not reported T790M mutation: __Positive __Negative __Not reported MET amplification: __Positive __Negative __Not reported
Date of Birth: Treatment Start Date: Stage: ECOG Performance Status:
ICD-10 Code:
BRAF: __V600E Mutation __ V600K Mutation __Wild type __Not reported PD-L1 expression: __1% to 49% __ >50% __Negative __Not reported RET gene rearrangement: __Absent __Present __Not reported Microsatellite instability: __dMMR/MSI-H __MSI-L __Not reported ROS1 rearrangement: __Positive __Negative __Not reported
Definitive Concurrent Chemoradiation Therapy
___Cisplatin and etoposide ___Paclitaxel and carboplatin
Adjuvant Therapy | EGFR Mutation Absent or Unknown
___Carboplatin and paclitaxel ___Cisplatin and gemcitabine (Gemzar) ___Cisplatin and pemetrexed (Alimta) ___Cisplatin and vinorelbine (Navelbine)
Advanced Disease (Stages IIIB-IV) | Squamous | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2
___Pembrolizumab (Keytruda)*, carboplatin, and paclitaxel
Advanced Disease (Stages IIIB-IV) | Squamous or Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2
___Atezolizumab (Tecentriq) (NON-SQUAMOUS ONLY) ___Cemiplimab-rwlc (Libtayo) ___Pembrolizumab (Keytruda)*
Advanced Disease (Stages IIIB-IV) | Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2
___Carboplatin, pemetrexed (Alimta), and pembrolizumab (Keytruda)*
* Administered at a dose of 200 mg every 3 weeks OR 400 mg every 6 weeks per the FDA label OR 2 mg/kg (up to a maximum of 200 mg) every 3 weeks, as clinically appropriate
In the setting of recurrent/metastatic NSCLC, a substitution of cisplatin for carboplatin (or vice-versa) will be considered a pathway option. Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.
Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.
8600 West Bryn Mawr Avenue South Tower ? Suite 800 Chicago, IL 60631
Last review: 11/1/2022 | Effective date: 1/16/2023
Appropriate.Safe.Affordable
? 2023 AIM Specialty Health
9017-0123
Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways (continued)
Advanced Disease (Stages IIIB-IV) | Squamous or Nonsquamous | Immunotherapy-Ineligible | First Line of Therapy (1st Line) | ECOG PS: 0-2
___Carboplatin and paclitaxel ___Carboplatin, paclitaxel, and bevacizumab (NON-SQUAMOUS ONLY) ___Cisplatin and gemcitabine (Gemzar) ___Cisplatin and pemetrexed (Alimta) (NON-SQUAMOUS ONLY)
Advanced Disease (Stages IIIB-IV) | Non-Squamous | Maintenance | ECOG PS: 0-2
___Continuation bevacizumab ___Continuation pemetrexed (Alimta) ___Pembrolizumab (Keytruda)* and pemetrexed (Alimta) (if previously treated with carboplatin, pemetrexed, and pembrolizumab) ___Switch pemetrexed (Alimta)
Advanced Disease (Stages IIIB-IV) | Second or Subsequent Lines of Therapy (2nd Line+) | ECOG PS: 0-2
___Atezolizumab (Tecentriq) (if no prior checkpoint inhibitors) ___Nivolumab (Opdivo) (if no prior checkpoint inhibitors) ___Carboplatin and paclitaxel ___Carboplatin and gemcitabine (Gemzar) ___Carboplatin and pemetrexed (Alimta)
Advanced Disease (Stages IIIB-IV) | ALK Positive | First Line of Therapy (1st Line)
___Alectinib (Alecensa) ___Lorlatinib (Lobrena)
Advanced Disease (Stages IIIB-IV) | EGFR Positive| First Line of Therapy (1st Line)
___Osimertinib (Tagrisso)
Advanced Disease (Stages IIIB-IV) | ALK or EGFR Positive | Second or Subsequent Lines of Therapy (2nd Line+) | ECOG PS: 0-2
___Carboplatin and paclitaxel ___Cisplatin and gemcitabine (Gemzar) ___Cisplatin and pemetrexed (Alimta)
Advanced Disease (Stages IIIB-IV) | EGFR Positive | ECOG PS: 3-4
___Erlotinib (Tarceva)
* Administered at a dose of 200 mg every 3 weeks OR 400 mg every 6 weeks per the FDA label OR 2 mg/kg (up to a maximum of 200 mg) every 3 weeks, as clinically appropriate
In the setting of recurrent/metastatic NSCLC, a substitution of cisplatin for carboplatin (or vice-versa) will be considered a pathway option. Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.
Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.
8600 West Bryn Mawr Avenue South Tower ? Suite 800 Chicago, IL 60631
Last review: 11/1/2022 | Effective date: 1/16/2023
Appropriate.Safe.Affordable
? 2023 AIM Specialty Health
9017-0123
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- moldx guardant360 plasma based comprehensive genomic profiling in non
- non small cell lung cancer treatment pathway map cancer care ontario
- systemic therapy for stage iv non small cell lung cancer american
- non small cell lung cancer kuwait cancer control center
- draft pmb definition guideline for non small cell lung cancer
- about non small cell lung cancer nsclc emd group
- tarceva nsclc billing codes genentech access solutions
- treating non small cell lung cancer american cancer society
- lung cancer non small cell lung cancer nsclc pathways
- what is non small cell lung cancer
Related searches
- lung cancer high blood pressure
- small cell lung cancer drugs
- chemotherapy small cell lung cancer
- lung cancer non smoker
- icd 10 small cell lung cancer code
- icd 10 non small cell carcinoma
- non small cell carcinoma icd 10
- non small cell lung cancer survival
- non smokers lung cancer statistics
- chemoregimen small cell lung cancer
- small cell lung cancer icd 10
- small cell lung cancer survival